<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04454684</url>
  </required_header>
  <id_info>
    <org_study_id>MED1</org_study_id>
    <nct_id>NCT04454684</nct_id>
  </id_info>
  <brief_title>A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders</brief_title>
  <acronym>MED1</acronym>
  <official_title>An Open-Label, Multi-Site Phase 2 Study of the Safety and Feasibility of MDMA-Assisted Psychotherapy for Eating Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Multidisciplinary Association for Psychedelic Studies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Multidisciplinary Association for Psychedelic Studies</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2, open-label, multi-site study will explore the safety and feasibility of&#xD;
      3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy and adjunctive caregiver&#xD;
      involvement in the treatment of 18 participants with eating disorders. The study will enroll&#xD;
      12 participants with anorexia nervosa restricting-type (AN-R) and six participants with binge&#xD;
      eating disorder (BED). A supportive caregiver, such as a parent or partner, for each&#xD;
      participant will also be recruited to participate in the study and receive non-drug&#xD;
      psychotherapy support. The study will consist of Preparatory Sessions, Experimental Sessions&#xD;
      of MDMA-assisted psychotherapy, as well as Individual and Dyadic Integrative Sessions.&#xD;
&#xD;
      A flexible dose of MDMA will be given during Experimental Sessions, ranging from 80 to 120 mg&#xD;
      with a supplemental half-dose of 40 or 60 mg 1.5 to 2 hours later, respectively, unless&#xD;
      contraindicated. The primary outcome measure is the change in Eating Disorder Examination&#xD;
      (EDE) results from Baseline to Visit 16 (Study Termination).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Both anorexia nervosa and binge eating disorder are associated with a variety of physical and&#xD;
      mental health conditions, including anxiety and depression, as well as lower health-related&#xD;
      quality of life. Remission rates for eating disorders vary widely from 27 to 85% and existing&#xD;
      treatments are relatively ineffective. It is widely accepted that deficits with emotion&#xD;
      processing are central to the developmental and maintenance of eating disorder symptoms.&#xD;
&#xD;
      3,4-methylenedioxymethamphetamine (MDMA) is a monoamine releaser and re-uptake inhibitor with&#xD;
      indirect effects of neurohormone release. MDMA produces anxiolytic and prosocial effects&#xD;
      while slowing identification of negative emotions, increasing acceptance of self and others,&#xD;
      and increasing ability to address emotionally upsetting topics. Thus, MDMA has theoretical&#xD;
      promise as a treatment for emotional processing, including dysregulation and poor&#xD;
      self-esteem, among people with eating disorders and may create a desirable psychological&#xD;
      state to enhance the therapeutic process.&#xD;
&#xD;
      This Phase 2, open-label, multi-site study will explore the safety and feasibility&#xD;
      MDMA-assisted psychotherapy and adjunctive caregiver involvement in the treatment of 18&#xD;
      participants with eating disorders. The study will enroll 12 participants with anorexia&#xD;
      nervosa restricting-type (AN-R) and six participants with binge eating disorder (BED). A&#xD;
      supportive caregiver, such as a parent or partner, for each participant will also be&#xD;
      recruited to participate in the study and receive non-drug psychotherapy support.&#xD;
&#xD;
      The study will consist of two Preparatory Sessions for each participant with an eating&#xD;
      disorder and one Preparatory Session for each caregiver participant. During the treatment&#xD;
      period, participants with eating disorders will undergo three Experimental Sessions of&#xD;
      MDMA-assisted psychotherapy, lasting approximately eight hours each. The first Experimental&#xD;
      Session will be followed by Individual Integrative Sessions for the participant with an&#xD;
      eating disorder and caregiver participant separately as well as a combined Dyadic Integrative&#xD;
      Session with both the participant with an eating disorder and their caregiver together. After&#xD;
      the second and third Experimental Session, just the participant with an eating disorder will&#xD;
      have an Individual Integrative Session before the combined Dyadic Integrative Session with&#xD;
      their caregiver.&#xD;
&#xD;
      The first Experimental Session will involve a dose of 80 mg of MDMA, followed by a&#xD;
      supplemental half-dose of 40 mg 1.5 to 2 hours later, unless contraindicated. The second and&#xD;
      third Experimental Sessions will involve a flexible dose of 80 or 120 mg of MDMA, followed by&#xD;
      a supplement half-dose of 40 or 60 mg, respectively, unless contraindicated. The primary&#xD;
      outcome measure is the change in Eating Disorder Examination (EDE) results at Baseline to&#xD;
      Visit 16 (Study Termination).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2023</start_date>
  <completion_date type="Anticipated">August 10, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Examining safety and effects of three sessions of MDMA-assisted psychotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This study will be open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Eating Disorder Examination Interview (EDE) Global Score from Baseline to Visit 16 (Study Termination)</measure>
    <time_frame>Baseline to 17 weeks post-enrollment</time_frame>
    <description>The Eating Disorder Examination Interview (EDE) is a semi-structured interview that assesses the frequency of key behavioral features of eating disorders as well as the severity of specific ED psychopathology. The EDE is widely considered to be the gold standard for assessing eating disorder pathology and can detect differences between individuals with anorexia nervosa and binge eating disorder.&#xD;
The EDE consists of four subscales: Restraint, Eating Concern, Shape Concern, and Weight Concern. The interview rates each question based on its frequency in the past month from a score of 0 (feature not present) to 6 (feature present every day). Subscale scores are calculated by totaling the scores in each subscale and dividing by the total number of items in the subscale. The overall or global score is calculated by summing the four subscale scores and dividing by four. The higher the score, the greater the eating disorder severity and frequency.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Anorexia Nervosa Restricting Type</condition>
  <condition>Binge-Eating Disorder</condition>
  <arm_group>
    <arm_group_label>AN-R: MDMA-assisted Psychotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three Experimental Sessions of MDMA-assisted psychotherapy. The first Experimental Session involves 80mg MDMA followed by a supplemental half-dose of 40 mg MDMA 1.5 to 2 hours later, unless contraindicated. The second and third Experimental Sessions involve a flexible dose of 80 or 120 mg of MDMA followed by a supplemental half-dose of 40 or 80 mg MDMA, respectively, 1.5 to 2 hours later, unless contraindicated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BED: MDMA-assisted Psychotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three Experimental Sessions of MDMA-assisted psychotherapy. The first Experimental Session involves 80mg MDMA followed by a supplemental half-dose of 40 mg MDMA 1.5 to 2 hours later, unless contraindicated. The second and third Experimental Sessions involve a flexible dose of 80 or 120 mg of MDMA followed by a supplemental half-dose of 40 or 80 mg MDMA, respectively, 1.5 to 2 hours later, unless contraindicated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caregivers: Psychotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Psychotherapy alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDMA</intervention_name>
    <description>Initial dose of 80 or 120 mg MDMA administered orally at the start of each of three psychotherapy sessions, followed by a supplemental half-dose of 40 to 60 mg MDMA 1.5 to 2.5 hours later, unless contraindicated.</description>
    <arm_group_label>AN-R: MDMA-assisted Psychotherapy</arm_group_label>
    <arm_group_label>BED: MDMA-assisted Psychotherapy</arm_group_label>
    <other_name>3,4-methylenedioxymethamphetamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Non-directive Psychotherapy</intervention_name>
    <description>Non-directive psychotherapy will be conducted during Experimental Sessions.</description>
    <arm_group_label>AN-R: MDMA-assisted Psychotherapy</arm_group_label>
    <arm_group_label>BED: MDMA-assisted Psychotherapy</arm_group_label>
    <other_name>Manualized MDMA-assisted psychotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychotherapy</intervention_name>
    <description>Psychotherapy will be conducted during Preparatory Sessions and Integrative Sessions.</description>
    <arm_group_label>AN-R: MDMA-assisted Psychotherapy</arm_group_label>
    <arm_group_label>BED: MDMA-assisted Psychotherapy</arm_group_label>
    <arm_group_label>Caregivers: Psychotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Eating Disorder (ED) Participants:&#xD;
&#xD;
          -  Are 21 to 65 years old.&#xD;
&#xD;
          -  Are assigned female at birth.&#xD;
&#xD;
          -  Are fluent in speaking and reading the English language and can provide written&#xD;
             informed consent.&#xD;
&#xD;
          -  Are able to swallow pills.&#xD;
&#xD;
          -  Agree to have study visits recorded to audio and video.&#xD;
&#xD;
          -  Are willing to include a consenting caregiver as a co-participant in elements of the&#xD;
             study with whom the study team will have regular contact. This person must be willing&#xD;
             and able to be reached by the investigators in case of emergency.&#xD;
&#xD;
          -  If connected to a psychotherapist at the time of recruitment into the study,&#xD;
             participants may not change therapists, change the frequency of therapy, or commence&#xD;
             any new type of therapy until after the Study Termination Visit, 1 month after the&#xD;
             final Experimental Session.&#xD;
&#xD;
          -  Have an identified Primary Care Physician (PCP) and provide consent for the&#xD;
             investigator to communicate with PCP, as needed.&#xD;
&#xD;
          -  If AN-R diagnosis, are currently participating in a recognized ED treatment program.&#xD;
&#xD;
          -  Are willing to sign a release for the investigators to communicate directly with their&#xD;
             therapist, physician if relevant, as well treatment providers where they were&#xD;
             currently or previously engaged an ED-specific episode of treatment.&#xD;
&#xD;
          -  Live within reasonable driving distance of the study site (equal to or less than an&#xD;
             estimated 2-hour drive from the study site).&#xD;
&#xD;
          -  If of childbearing potential, must have a negative pregnancy test at study entry and&#xD;
             prior to each Experimental Session, and must agree to use adequate birth control&#xD;
&#xD;
          -  Agree to inform the investigators within 48 hours of any medical conditions and&#xD;
             procedures.&#xD;
&#xD;
          -  Agree to lifestyle modifications, comply with requirements for fasting and refraining&#xD;
             from certain medications prior to Experimental Sessions, not participate in any other&#xD;
             interventional clinical trials during the duration of the study, remain overnight at&#xD;
             the study site (or appropriate location approved by the research team) after each&#xD;
             Experimental Session, not operate a vehicle within 24 hours after MDMA administration,&#xD;
             and commit to medication dosing, therapy, and study procedures.&#xD;
&#xD;
          -  Have Anorexia Nervosa, Restricting Type or Binge Eating Disorder.&#xD;
&#xD;
          -  Current or past treatment were not successful to retain remission&#xD;
&#xD;
          -  Have a BMI &gt; 15 kg/m2 and are medically stable according to screening&#xD;
             Electrocardiogram (ECG), blood pressure monitoring, and blood and urine laboratory&#xD;
             screening results.&#xD;
&#xD;
        Exclusion Criteria for Eating Disorder (ED) Participants:&#xD;
&#xD;
          -  Are not able to give adequate informed consent.&#xD;
&#xD;
          -  Have any current problem which, in the opinion of the investigator or Medical Monitor,&#xD;
             might interfere with participation.&#xD;
&#xD;
          -  Cannot identify a supportive caregiver to participate in the study (or the caregiver&#xD;
             does not meet eligibility criteria).&#xD;
&#xD;
          -  Have a blood or needle phobia that interferes with obtaining necessary blood work&#xD;
&#xD;
          -  Have a history of significant medical disorders&#xD;
&#xD;
          -  Have any current problematic patterns of alcohol or other substance use&#xD;
&#xD;
          -  Require use of prohibited concomitant medications for this study, including those that&#xD;
             prolong the QT/QTc interval during Experimental Sessions.&#xD;
&#xD;
          -  Have a history of any medical condition that could make receiving a sympathomimetic&#xD;
             drug harmful because of increases in blood pressure and heart rate.&#xD;
&#xD;
          -  Have uncontrolled hypertension or history of ventricular arrhythmia.&#xD;
&#xD;
          -  Have Wolff-Parkinson-White syndrome or any other accessory pathway.&#xD;
&#xD;
          -  Have a marked Baseline prolongation of QTcF interval (e.g., repeated demonstration of&#xD;
             a QTcF interval &gt; 450 ms).&#xD;
&#xD;
          -  Have a history of additional risk factors for Torsade de pointes (e.g., heart failure,&#xD;
             hypokalemia, family history of Long QT Syndrome).&#xD;
&#xD;
          -  Have symptomatic liver disease.&#xD;
&#xD;
          -  Have a history of non-ED-symptom-related hyponatremia or hyperthermia.&#xD;
&#xD;
          -  Are pregnant or nursing, or are persons of childbearing potential who are not&#xD;
             practicing (or not willing to practice) an effective means of birth control.&#xD;
&#xD;
          -  Are assessed to be medically unstable&#xD;
&#xD;
        Inclusion Criteria for Caregiver (CG) Participants:&#xD;
&#xD;
          -  Are fluent in speaking and reading the English language and can provide written&#xD;
             informed consent.&#xD;
&#xD;
          -  Are at least 18 years old.&#xD;
&#xD;
          -  Are the parent, partner, or other significant caregiver of the ED Participant.&#xD;
&#xD;
          -  Are involved in caregiving at least 2 hours a week (i.e. companionship, meal support,&#xD;
             emotional support, driving to appointments, financial support, etc.).&#xD;
&#xD;
          -  Are willing to provide their loved one with meal/symptom support and emotional support&#xD;
             throughout the study.&#xD;
&#xD;
          -  Live within reasonable driving distance of the study site&#xD;
&#xD;
          -  If in ongoing psychotherapy at the time participants are recruited into the study,&#xD;
             caregiver participants may continue to see their outside therapist during the course&#xD;
             of the study. Caregiver participants must sign a release for the investigators to&#xD;
             communicate directly with their therapist. CG Participants may not change therapists,&#xD;
             increase the frequency of therapy, or commence any new type of therapy until after&#xD;
             their Study Termination Visit.&#xD;
&#xD;
          -  Are willing to commit to Preparatory and Integrative Sessions, completion of&#xD;
             evaluation instruments and other study procedures, and being contacted for all&#xD;
             necessary telephone contacts.&#xD;
&#xD;
          -  Agree to have study visits recorded to audio and video.&#xD;
&#xD;
        Exclusion Criteria for Caregiver (CG) Participants:&#xD;
&#xD;
          -  Have a current eating disorder.&#xD;
&#xD;
          -  Are unable to give adequate informed consent.&#xD;
&#xD;
          -  Report any current problem which in the opinion of the investigator or Medical Monitor&#xD;
             might interfere with enrollment or ongoing participation.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Assigned female at birth</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Gitchel, PhD</last_name>
    <role>Study Director</role>
    <affiliation>MAPS PBC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruitment Officer</last_name>
    <phone>804-513-4687</phone>
    <email>recruitment@mapsbcorp.com</email>
  </overall_contact>
  <reference>
    <citation>Cooper, Z. and C. Fairburn, The eating disorder examination: A semi-structured interview for the assessment of the specific psychopathology of eating disorders. International journal of eating disorders, 1987. 6(1): p. 1-8.</citation>
  </reference>
  <reference>
    <citation>Fairburn, C., Z. Cooper, and M. O'Connor, Eating Disorder Examination (Edition 17.0D; April, 2014). 2014: https://www.corc.uk.net/media/1951/ede_170d.pdf.</citation>
  </reference>
  <reference>
    <citation>Keel PK, Brown TA. Update on course and outcome in eating disorders. Int J Eat Disord. 2010 Apr;43(3):195-204. doi: 10.1002/eat.20810.</citation>
    <PMID>20186717</PMID>
  </reference>
  <verification_date>August 2023</verification_date>
  <study_first_submitted>June 26, 2020</study_first_submitted>
  <study_first_submitted_qc>June 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2020</study_first_posted>
  <last_update_submitted>August 10, 2023</last_update_submitted>
  <last_update_submitted_qc>August 10, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Bulimia</mesh_term>
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
    <mesh_term>Binge-Eating Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-Methyl-3,4-methylenedioxyamphetamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will share outcome data appearing in any published reports upon request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data and study-related documents will be available wehn all participants have completed the study.</ipd_time_frame>
    <ipd_access_criteria>Interested persons should correspond with the central contact for the multi-site study.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04454684
org study id: MED1
nct id: NCT04454684
lead sponsor: 
is fda regulated drug: Yes
is fda regulated device: No
This Phase 2, open-label, multi-site study will explore the safety and feasibility of
      3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy and adjunctive caregiver
      involvement in the treatment of 18 participants with eating disorders. The study will enroll
      12 participants with anorexia nervosa restricting-type (AN-R) and six participants with binge
      eating disorder (BED). A supportive caregiver, such as a parent or partner, for each
      participant will also be recruited to participate in the study and receive non-drug
      psychotherapy support. The study will consist of Preparatory Sessions, Experimental Sessions
      of MDMA-assisted psychotherapy, as well as Individual and Dyadic Integrative Sessions.

      A flexible dose of MDMA will be given during Experimental Sessions, ranging from 80 to 120 mg
      with a supplemental half-dose of 40 or 60 mg 1.5 to 2 hours later, respectively, unless
      contraindicated. The primary outcome measure is the change in Eating Disorder Examination
      (EDE) results from Baseline to Visit 16 (Study Termination).
Both anorexia nervosa and binge eating disorder are associated with a variety of physical and
      mental health conditions, including anxiety and depression, as well as lower health-related
      quality of life. Remission rates for eating disorders vary widely from 27 to 85% and existing
      treatments are relatively ineffective. It is widely accepted that deficits with emotion
      processing are central to the developmental and maintenance of eating disorder symptoms.

      3,4-methylenedioxymethamphetamine (MDMA) is a monoamine releaser and re-uptake inhibitor with
      indirect effects of neurohormone release. MDMA produces anxiolytic and prosocial effects
      while slowing identification of negative emotions, increasing acceptance of self and others,
      and increasing ability to address emotionally upsetting topics. Thus, MDMA has theoretical
      promise as a treatment for emotional processing, including dysregulation and poor
      self-esteem, among people with eating disorders and may create a desirable psychological
      state to enhance the therapeutic process.

      This Phase 2, open-label, multi-site study will explore the safety and feasibility
      MDMA-assisted psychotherapy and adjunctive caregiver involvement in the treatment of 18
      participants with eating disorders. The study will enroll 12 participants with anorexia
      nervosa restricting-type (AN-R) and six participants with binge eating disorder (BED). A
      supportive caregiver, such as a parent or partner, for each participant will also be
      recruited to participate in the study and receive non-drug psychotherapy support.

      The study will consist of two Preparatory Sessions for each participant with an eating
      disorder and one Preparatory Session for each caregiver participant. During the treatment
      period, participants with eating disorders will undergo three Experimental Sessions of
      MDMA-assisted psychotherapy, lasting approximately eight hours each. The first Experimental
      Session will be followed by Individual Integrative Sessions for the participant with an
      eating disorder and caregiver participant separately as well as a combined Dyadic Integrative
      Session with both the participant with an eating disorder and their caregiver together. After
      the second and third Experimental Session, just the participant with an eating disorder will
      have an Individual Integrative Session before the combined Dyadic Integrative Session with
      their caregiver.

      The first Experimental Session will involve a dose of 80 mg of MDMA, followed by a
      supplemental half-dose of 40 mg 1.5 to 2 hours later, unless contraindicated. The second and
      third Experimental Sessions will involve a flexible dose of 80 or 120 mg of MDMA, followed by
      a supplement half-dose of 40 or 60 mg, respectively, unless contraindicated. The primary
      outcome measure is the change in Eating Disorder Examination (EDE) results at Baseline to
      Visit 16 (Study Termination).
allocation: Non-Randomized
intervention model: Parallel Assignment
intervention model description: Examining safety and effects of three sessions of MDMA-assisted psychotherapy
primary purpose: Treatment
masking: None (Open Label)
masking description: This study will be open label
measure: Change in Eating Disorder Examination Interview (EDE) Global Score from Baseline to Visit 16 (Study Termination)
time frame: Baseline to 17 weeks post-enrollment
description: The Eating Disorder Examination Interview (EDE) is a semi-structured interview that assesses the frequency of key behavioral features of eating disorders as well as the severity of specific ED psychopathology. The EDE is widely considered to be the gold standard for assessing eating disorder pathology and can detect differences between individuals with anorexia nervosa and binge eating disorder.
The EDE consists of four subscales: Restraint, Eating Concern, Shape Concern, and Weight Concern. The interview rates each question based on its frequency in the past month from a score of 0 (feature not present) to 6 (feature present every day). Subscale scores are calculated by totaling the scores in each subscale and dividing by the total number of items in the subscale. The overall or global score is calculated by summing the four subscale scores and dividing by four. The higher the score, the greater the eating disorder severity and frequency.
arm group label: AN-R: MDMA-assisted Psychotherapy
arm group type: Experimental
description: Three Experimental Sessions of MDMA-assisted psychotherapy. The first Experimental Session involves 80mg MDMA followed by a supplemental half-dose of 40 mg MDMA 1.5 to 2 hours later, unless contraindicated. The second and third Experimental Sessions involve a flexible dose of 80 or 120 mg of MDMA followed by a supplemental half-dose of 40 or 80 mg MDMA, respectively, 1.5 to 2 hours later, unless contraindicated.
arm group label: BED: MDMA-assisted Psychotherapy
arm group type: Experimental
description: Three Experimental Sessions of MDMA-assisted psychotherapy. The first Experimental Session involves 80mg MDMA followed by a supplemental half-dose of 40 mg MDMA 1.5 to 2 hours later, unless contraindicated. The second and third Experimental Sessions involve a flexible dose of 80 or 120 mg of MDMA followed by a supplemental half-dose of 40 or 80 mg MDMA, respectively, 1.5 to 2 hours later, unless contraindicated.
arm group label: Caregivers: Psychotherapy
arm group type: Experimental
description: Psychotherapy alone
intervention type: Drug
intervention name: MDMA
description: Initial dose of 80 or 120 mg MDMA administered orally at the start of each of three psychotherapy sessions, followed by a supplemental half-dose of 40 to 60 mg MDMA 1.5 to 2.5 hours later, unless contraindicated.
arm group label: AN-R: MDMA-assisted Psychotherapy
arm group label: BED: MDMA-assisted Psychotherapy
other name: 3,4-methylenedioxymethamphetamine
intervention type: Behavioral
intervention name: Non-directive Psychotherapy
description: Non-directive psychotherapy will be conducted during Experimental Sessions.
arm group label: AN-R: MDMA-assisted Psychotherapy
arm group label: BED: MDMA-assisted Psychotherapy
other name: Manualized MDMA-assisted psychotherapy
intervention type: Behavioral
intervention name: Psychotherapy
description: Psychotherapy will be conducted during Preparatory Sessions and Integrative Sessions.
arm group label: AN-R: MDMA-assisted Psychotherapy
arm group label: BED: MDMA-assisted Psychotherapy
arm group label: Caregivers: Psychotherapy
criteria: 
gender: Female
gender based: Yes
gender description: Assigned female at birth
minimum age: 21 Years
maximum age: 65 Years
healthy volunteers: No
last name: George Gitchel, PhD
role: Study Director
affiliation: MAPS PBC
last name: Recruitment Officer
phone: 804-513-4687
email: recruitment@mapsbcorp.com
citation: Cooper, Z. and C. Fairburn, The eating disorder examination: A semi-structured interview for the assessment of the specific psychopathology of eating disorders. International journal of eating disorders, 1987. 6(1): p. 1-8.
citation: Fairburn, C., Z. Cooper, and M. O'Connor, Eating Disorder Examination (Edition 17.0D; April, 2014). 2014: https://www.corc.uk.net/media/1951/ede_170d.pdf.
citation: Keel PK, Brown TA. Update on course and outcome in eating disorders. Int J Eat Disord. 2010 Apr;43(3):195-204. doi: 10.1002/eat.20810.
PMID: 20186717
responsible party type: Sponsor
mesh term: Anorexia
mesh term: Bulimia
mesh term: Feeding and Eating Disorders
mesh term: Anorexia Nervosa
mesh term: Binge-Eating Disorder
mesh term: N-Methyl-3,4-methylenedioxyamphetamine
sharing ipd: Yes
ipd description: We will share outcome data appearing in any published reports upon request.
ipd info type: Study Protocol
ipd info type: Statistical Analysis Plan (SAP)
ipd info type: Informed Consent Form (ICF)
ipd time frame: Data and study-related documents will be available wehn all participants have completed the study.
ipd access criteria: Interested persons should correspond with the central contact for the multi-site study.